DeepMed Research

Pegvisomant

Generic Name: Pegvisomant

Brand Names: Somavert

Drug Type: Biotech

CAS Number: 218620-50-9

Unique Ingredient Identifier: N824AOU5XV

Background: Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.

Indication: Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.

Associated Conditions: Acromegaly

Clinical Trials

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

Phase 2

Recruiting

Conditions: Partial Lipodystrophy
Insulin Receptor Mutation

Interventions: Drug: Pegvisomant

First Posted Date: 2022-07-22

Last Posted Date: 2025-04-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 25

Registration Number: NCT05470504

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Korean Regulatory Post Marketing Surveillance for Somavert

Recruiting

Conditions: Acromegaly

Interventions: Drug: Somavert

First Posted Date: 2021-11-23

Last Posted Date: 2025-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT05131100

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess

Phase 3

Recruiting

Conditions: Pituitary Disease

Interventions: Drug: Pegvisomant

First Posted Date: 2019-03-20

Last Posted Date: 2025-04-25

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 120

Registration Number: NCT03882034

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Bone MicroArchitecture in Acromegaly

Completed

Conditions: Osteoporosis Risk
Acromegaly

Interventions: Drug: Pegvisomant

First Posted Date: 2017-07-21

Last Posted Date: 2021-07-13

Lead Sponsor: Columbia University

Target Recruit Count: 77

Registration Number: NCT03225040

Locations: 🇺🇸
Neuroendocrine Unit and Pituitary Center, Columbia University, New York, New York, United States

Strict IGF-1 Control in Acromegaly

Phase 3

Completed

Conditions: Acromegaly

Interventions: Drug: Pegvisomant

First Posted Date: 2016-11-02

Last Posted Date: 2021-11-22

Lead Sponsor: Unity Health Toronto

Target Recruit Count: 10

Registration Number: NCT02952885

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
St. Joseph Health Care London, London, Ontario, Canada
🇨🇦
Centre hospitalier universitaire de Québec-Université Laval, Quebec City, Quebec, Canada

and more 2 locations

Pasireotide LAR and Pegvisomant Study in Acromegaly

Phase 4

Conditions: Acromegaly

Interventions: Drug: Pasireotide LAR 60 mg
Drug: Pegvisomant

First Posted Date: 2016-01-29

Last Posted Date: 2016-08-03

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 60

Registration Number: NCT02668172

Locations: 🇳🇱
Erasmus Medical Center, Rotterdam, South Holland, Netherlands

Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting

Not Applicable

Completed

Conditions: Healthy

Interventions: Other: Fasting
Drug: Saline
Drug: Pegvisomant

First Posted Date: 2015-07-16

Last Posted Date: 2016-11-23

Lead Sponsor: University of Aarhus

Target Recruit Count: 10

Registration Number: NCT02500095

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes

Phase 2

Completed

Conditions: Diabetes
Metabolic Syndrome
Insulin Resistance

Interventions: Drug: pegvisomant

First Posted Date: 2013-12-30

Last Posted Date: 2017-04-24

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 6

Registration Number: NCT02023918

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 2 x 15 mg/mL pegvisomant
Drug: 1 x 30 mg/mL pegvisomant

First Posted Date: 2013-07-09

Last Posted Date: 2013-12-12

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT01893866

Locations: 🇧🇪
Pfizer Investigational Site, Brussels, Belgium

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

Not Applicable

Conditions: Adults Growth Hormone Deficiency.

Interventions: Drug: Pegvisomant
Drug: Regular insulin

First Posted Date: 2013-03-05

Last Posted Date: 2013-10-24

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 10

Registration Number: NCT01804413

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy